Best eQMS for Medical Device Startups

Most medical device startups adopt an eQMS once Design Controls and DHF are required to be evidenced — usually before design freeze and well before ISO 13485 certification or FDA 510(k) submission. Some adopt earlier (during early R&D) using lighter-weight tools and migrate at design transfer. The decision usually hinges on certification timeline, investor diligence, and whether the team can sustain a paper-or-spreadsheet system through audit.

ISO 13485:2016 requires Document Control, Records, Management Responsibility (Quality Manual, Management Review), Resource Management (Training), Product Realisation (Design Controls + DHF where applicable), and Measurement / Analysis / Improvement (Internal Audits, CAPA, Nonconformance, Customer Feedback). The eQMS should support all of these with audit-trailed records, e-signatures (for FDA Part 11 alignment), and traceable Design Controls outputs. Risk Management (ISO 14971) is a core companion.

Most life-sciences eQMS vendors are proposal-based without published list prices. Pricing typically scales by user count, module scope, and validation depth. SMB / startup tiers exist at most vendors but specific dollar figures are rarely public. Compare like-for-like by sending each vendor the same module list (Documents, Training, CAPA, Nonconformance, Audits, Risk, Design Controls / DHF), user counts, and integration list. Validation evidence delivered (full CSV pack vs templates) is a major TCO factor for the certification audit.

Time-to-implementation depends on module scope, headcount, integration complexity, and validation depth. SMB medical device startups deploying 3 to 5 modules with Complere typically ship in weeks, full CSV protocol pack included. Comparable vendors typically range from a few weeks to several months for full validation. Audit-readiness for ISO 13485 certification is then a function of how thoroughly the team has populated controlled documents, run training, completed internal audits, and closed CAPAs.

Medical-device-exclusive vendors (e.g. Greenlight Guru) ship Design Controls, DHF, and Clinical Evidence as first-class with deep MedTech-specialist onboarding. Multi-vertical vendors (e.g. Complere) cover medical device alongside pharma and biotech, which matters if the company expects to expand into combination products, biotech-derived therapies, or in-licensed pharma assets. If the long-term portfolio is medical-device-only, a specialist may be a better fit; if growth into combination or pharma is on the roadmap, a multi-vertical platform avoids a future re-platforming.

Effective 2026-02-02, the FDA QMSR (Quality Management System Regulation) replaces 21 CFR Part 820 for medical devices. The QMSR aligns FDA’s quality system requirements with ISO 13485:2016 — most ISO 13485-aligned QMS programmes already meet QMSR expectations. Differences: QMSR retains FDA-specific provisions on labelling, UDI, complaint handling, and reporting, layered on top of ISO 13485. eQMS platforms aligned to ISO 13485 + Part 820 generally remain valid under QMSR; verify your vendor’s QMSR alignment statement.

ISO 13485 itself does not mandate electronic signatures — it requires that records demonstrate conformity to requirements and the effective operation of the QMS. If you elect to use electronic signatures (which most modern eQMS implementations do), then FDA 21 CFR Part 11 (US market) or EU GMP Annex 11 (EU market) requirements apply to the e-signature implementation: signer identification, signature manifestation (printed name, date, meaning), and link to the record signed. Wet signatures on printed records are still permitted; e-signatures are an alternative, not a requirement.

A Design History File (DHF) is the body of records demonstrating the design was developed in accordance with the approved Design and Development plan and Design Controls (21 CFR Part 820.30 / FDA QMSR / ISO 13485 §7.3). It typically contains design inputs, design outputs, design reviews, verification and validation results, design transfer records, and design changes. An eQMS supports the DHF either as a first-class Design Controls module (Greenlight Guru, Qualio) or through linked records across Documents, Risk, Change, and CAPA (Complere). Either approach is acceptable to auditors provided traceability across the design lifecycle is demonstrable.

ISO 14971:2019 requires a documented risk management process across the device lifecycle: hazard identification, risk estimation (severity × probability), risk evaluation against acceptability criteria, risk control (design / protective measures / information for safety), residual risk evaluation, overall residual risk acceptability, and post-production information feedback. Common methodologies: FMEA (Failure Mode Effects Analysis), DFMEA (Design FMEA), PHA (Preliminary Hazard Analysis), Fault Tree Analysis. An eQMS Risk module should support these methodologies, link risk records to design inputs/outputs and CAPAs, and retain records for the lifetime of the device.

510(k) is the FDA submission demonstrating that a device is substantially equivalent to a legally marketed predicate device, and is required before marketing most Class II devices in the US. The submission includes device description, intended use, comparison to predicate, performance data (bench, animal, clinical where required), labelling, and quality system declarations. The eQMS supports 510(k) by maintaining the DHF (design records), risk file (ISO 14971), V&V records, and quality system documentation that the submission references and the FDA may inspect post-clearance.